Explore the vast range of titles available.

Natural products-bioactive compounds derived from plants, microbes, fungi, and marine organisms-have shaped the pharmaceutical landscape for decades [...].Natural products-bioactive compounds derived from plants, microbes, fungi, and marine organisms-have shaped the pharmaceutical landscape for decades [...].

In recent decades, the identification of thousands of lead compounds, through development of analytical, synthetic, and computational techniques has occurred [...].In recent decades, the identification of thousands of lead compounds, through development of analytical, synthetic, and computational techniques has occurred [...].

This reference summarizes information about pharmaceuticals that can target infectious strains of coronaviruses to neutralize infections. Chapters focus on SARS-CoV-2, drug discovery methods and natural methods to combat the virus, which is a causative agent of COVID-19. Specifically, the book presents 5 chapters written by expert scholar on the following topics: Structure-Based Drug Discovery Approaches Applied to SARS-CoV-2 (the causative agent COVID- 19)Potential Antiviral Medicinal Plants against Novel SARS-CoV-2Infections Caused by SARS Coronaviruses: Main Characteristics, Targets And Inhibitors Natural Sourced Traditional Indian and Chinese Medicines to Combat COVID- 19Peptidomimetic and Peptide-Derived Agents Against 3CLpro from Coronaviruses The book contents present both conventional drug design and traditional approaches to discovering relevant drugs in an easy-to-read approach, which is supplemented by bibliographic references. It is intended as a reference for students (pharmacology, pharmacy) and researchers (virology) who are seeking information about antiviral drugs that can be used against coronaviruses.

Chalcones are direct precursors in the biosynthesis of flavonoids. They have an α,β-unsaturated carbonyl system which gives them broad biological properties. Among the biological properties exerted by chalcones, their ability to suppress tumors stands out, in addition to their low toxicity. In this perspective, the present work explores the role of natural and synthetic chalcones and their anticancer activity in vitro reported in the last four years from 2019 to 2023. Moreover, we carried out a partial least square (PLS) analysis of the biologic data reported for colon adenocarcinoma lineage HCT-116. Information was obtained from the Web of Science database. Our in silico analysis identified that the presence of polar radicals such as hydroxyl and methoxyl contributed to the anticancer activity of chalcones derivatives. We hope that the data presented in this work will help researchers to develop effective drugs to inhibit colon adenocarcinoma in future works.

Objective: This study evaluated the antifungal activity of cinnamaldehyde on Candida spp. In vitro and in situ assays were carried out to test cinnamaldehyde for its anti-Candida effects, antibiofilm activity, effects on fungal micromorphology, antioxidant activity, and toxicity on keratinocytes and human erythrocytes. Statistical analysis was performed considering α = 5%. Results: The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of cinnamaldehyde ranged from 18.91 μM to 37.83 μM. MIC values did not change in the presence of 0.8 M sorbitol, whereas an 8-fold increase was observed in the presence of ergosterol, suggesting that cinnamaldehyde may act on the cell membrane, which was subsequently confirmed by docking analysis. The action of cinnamaldehyde likely includes binding to enzymes involved in the formation of the cytoplasmic membrane in yeast cells. Cinnamaldehyde-treated microcultures showed impaired cellular development, with an expression of rare pseudo-hyphae and absence of chlamydoconidia. Cinnamaldehyde reduced biofilm adherence by 64.52% to 33.75% (p < 0.0001) at low concentrations (378.3–151.3 µM). Cinnamaldehyde did not show antioxidant properties. Conclusions: Cinnamaldehyde showed fungicidal activity through a mechanism of action likely related to ergosterol complexation; it was non-cytotoxic to keratinocytes and human erythrocytes and showed no antioxidant activity.

Bioremediation offers a sustainable and eco-friendly approach for addressing petroleum contamination. In this study, we investigated the hydrocarbon-degrading potential of Microbacter sp. EMBS2025, a strain previously isolated and characterized for its biosurfactant-producing capabilities. The strain was cultivated using varying concentrations of crude oil as the sole carbon source, where it demonstrated robust growth and efficient degradation of both alkanes and aromatic hydrocarbons. Whole-genome sequencing was performed using the Illumina Novaseq 6000 platform, yielding approximately 33.4 million high-quality reads with a sequencing depth (~ 1482 ×). The assembled genome spans 3.52 Mb and comprises 3237 coding sequences (CDS), 19 miscellaneous RNAs, 3 rRNAs, 51 tRNAs, and 1 tmRNA. The genome assembly achieved 100% completeness, providing a fully reconstructed genome. Functional annotation revealed a metabolically versatile profile, including key genes involved in biosurfactant synthesis ( ppsC, treS, treY, mmpL3, otsA , and rhlG_1/rhlG_2) and hydrocarbon degradation ( alkB, sadH, yghA, nuo, gap , BVMO, cat, pca , and ben ) , highlighting its strong oxidation potential. Orthogroup analysis identified unique orthologous groups within the strain, while Average Nucleotide Identity (ANI) analysis suggests that Microbacter sp. EMBS2025 may represent a novel species within the Microbacterium genus. Variant annotation revealed a genome enriched with high-impact variants, with SNPs accounting for 66–68% of the total. The demonstrated bioremediation potential of Microbacter sp. EMBS2025 offers a sustainable solution for oil pollution, contributing to cleaner environments, reduced health risks, and enhanced water quality. The application of this strain in oil-contaminated environments holds significant promise for protecting public health by reducing toxic exposure risks, restoring clean water sources, and supporting agricultural and economic activities in affected communities.

Leishmaniasis refers to a complex of diseases, caused by the intracellular parasitic protozoans belonging to the genus Leishmania. Among the three types of disease manifestations, the most severe type is visceral leishmaniasis, which is caused by Leishmania donovani, and is diagnosed in more than 20,000 cases annually, worldwide. Because the current therapeutic options for disease treatment are associated with several limitations, the identification of new potential leads/drugs remains necessary. In this study, a combined approach was used, based on two different virtual screening (VS) methods, which were designed to select promising antileishmanial agents from among the entire sesquiterpene lactone (SL) dataset registered in SistematX, a web interface for managing a secondary metabolite database that is accessible by multiple platforms on the Internet. Thus, a ChEMBL dataset, including 3159 and 1569 structures that were previously tested against L. donovani amastigotes and promastigotes in vitro, respectively, was used to develop two random forest models, which performed with greater than 74% accuracy in both the cross-validation and test sets. Subsequently, a ligand-based VS assay was performed against the 1306 SistematX-registered SLs. In parallel, the crystal structures of three L. donovani target proteins, N-myristoyltransferase, ornithine decarboxylase, and mitogen-activated protein kinase 3, and a homology model of pteridine reductase 1 were used to perform a structure-based VS, using molecular docking, of the entire SistematX SL dataset. The consensus analysis of these two VS approaches resulted in the normalization of probability scores and identified 13 promising, enzyme-targeting, antileishmanial SLs from SistematX that may act against L. donovani.Graphic abstractA combined approach based on two different virtual screening methods (structure-based and ligand-based) was performed using an in-house dataset composed of 1306 sesquiterpene lactones to identify potential antileishmanial (Leishmania donovani) structures.

Rheumatoid arthritis, arthrosis and gout, among other chronic inflammatory diseases are public health problems and represent major therapeutic challenges. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prescribed clinical treatments, despite their severe side effects and their exclusive action in improving symptoms, without effectively promoting the cure. However, recent advances in the fields of pharmacology, medicinal chemistry, and chemoinformatics have provided valuable information and opportunities for development of new anti-inflammatory drug candidates. For drug design and discovery, thiophene derivatives are privileged structures. Thiophene-based compounds, like the commercial drugs Tinoridine and Tiaprofenic acid, are known for their anti-inflammatory properties. The present review provides an update on the role of thiophene-based derivatives in inflammation. Studies on mechanisms of action, interactions with receptors (especially against cyclooxygenase (COX) and lipoxygenase (LOX)), and structure-activity relationships are also presented and discussed. The results demonstrate the importance of thiophene-based compounds as privileged structures for the design and discovery of novel anti-inflammatory agents. The studies reveal important structural characteristics. The presence of carboxylic acids, esters, amines, and amides, as well as methyl and methoxy groups, has been frequently described, and highlights the importance of these groups for anti-inflammatory activity and biological target recognition, especially for inhibition of COX and LOX enzymes.

Colorectal cancer remains a significant cause of mortality worldwide. A spiro-acridine derivative, (E)-1′-((4-bromobenzylidene)amino)-5′-oxo-1′,5′-dihydro-10H-spiro[acridine-9,2′-pyrrole]-4′-carbonitrile (AMTAC-19), showed significant cytotoxicity in HCT-116 colorectal carcinoma cells (half maximal inhibitory concentration, IC50 = 10.35 ± 1.66 µM) and antioxidant effects after 48 h of treatment. In this study, Molegro Virtual Docker v.6.0.1 software was used to investigate the interactions between AMTAC-19 and the Extracellular Signal-Regulated Kinase 1 (ERK1), c-Jun N-terminal Kinase 1 (JNK1), and p38 Mitogen-Activated Protein Kinase α (p38α MAPK). In vitro assays were conducted in HCT-116 cells to evaluate the effect of AMTAC-19 on the modulation of these proteins’ activities using flow cytometry. Furthermore, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in the presence or absence of ERK1/2, JNK, and p38 MAPK inhibitors was used to evaluate the involvement of these enzymes in AMTAC-19 cytotoxicity. ROS production was assessed using the 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) assay at various incubation times (30 min, 1 h, 6 h, 12 h, and 24 h), and the MTT assay using N-acetyl-L-cysteine (NAC) was performed. In silico results indicated that AMTAC-19 interacts with ERK1, JNK1, and p38α MAPK. Additionally, AMTAC-19 activated ERK1/2 and JNK1 in HCT-116 cells, and its cytotoxicity was significantly reduced in the presence of ERK1/2 and JNK inhibitors. AMTAC-19 also induced a significant increase in ROS production (30 min and 1 h), while NAC pretreatment reduced its cytotoxicity. These findings support AMTAC-19′s in vitro antitumor effect through ROS-dependent activation of ERK and JNK pathways.